Trial · NCT01817530
Participant flow24
How many started, completed or left each group, period by period.
1 to 20 of 24
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1: Placebo | 65 | |
| Overall Study | STARTED | Cohort 1: Elagolix 300 mg BID | 65 | |
| Overall Study | STARTED | Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD | 64 | |
| Overall Study | STARTED | Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD | 65 | |
| Overall Study | STARTED | Cohort 2: Placebo | 78 | |
| Overall Study | STARTED | Cohort 2: Elagolix 600 mg QD | 77 | |
| Overall Study | STARTED | Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD | 76 | |
| Overall Study | STARTED | Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD | 77 | |
| Overall Study | COMPLETED | Cohort 1: Placebo | 50 | |
| Overall Study | COMPLETED | Cohort 1: Elagolix 300 mg BID | 52 | |
| Overall Study | COMPLETED | Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD | 53 | |
| Overall Study | COMPLETED | Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD | 52 | |
| Overall Study | COMPLETED | Cohort 2: Placebo | 67 | |
| Overall Study | COMPLETED | Cohort 2: Elagolix 600 mg QD | 58 | |
| Overall Study | COMPLETED | Cohort 2: Elagolix 600 mg QD Plus LD E2/NETA QD | 53 | |
| Overall Study | COMPLETED | Cohort 2: Elagolix 600 mg QD Plus SD E2/NETA QD | 53 | |
| Overall Study | NOT COMPLETED | Cohort 1: Placebo | 15 | |
| Overall Study | NOT COMPLETED | Cohort 1: Elagolix 300 mg BID | 13 | |
| Overall Study | NOT COMPLETED | Cohort 1: Elagolix 300 mg BID Plus LD E2/NETA QD | 11 | |
| Overall Study | NOT COMPLETED | Cohort 1: Elagolix 300 mg BID Plus SD E2/NETA QD | 13 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01817530/flow